



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | |
|--|-----------|---|
| (51) International Patent Classification 7 : C07K 14/49, C12N 5/02, A61P 17/02, 21/00, 9/10 | A2 | (11) International Publication Number: WO 00/59940 (43) International Publication Date: 12 October 2000 (12.10.00) |
| (21) International Application Number: PCT/US00/06427 (22) International Filing Date: 24 March 2000 (24.03.00) (30) Priority Data: 60/127,913 6 April 1999 (06.04.99) US (71) Applicant (for all designated States except US): ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center, Indi- anapolis, IN 46285 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): HAMMOND, Lisa, Janine [US/US]; 1498 Pondview Drive, Carmel, IN 46032 (US). NA, Songqing [CN/US]; 10756 Independence Way, Carmel, IN 46032 (US). (74) Agents: WALSH, Andrea, C. et al.; Eli Lilly And Company, Lilly Corporate Center, Indianapolis, IN 46285 (US). | | (81) Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i> |
| (54) Title: PLATELET-DERIVED GROWTH FACTOR RELATED GENE AND PROTEIN (57) Abstract The invention provides methods for promoting wound healing, and methods for stimulating tissue regeneration as well as methods for preventing or treating atherosclerosis in a patient in need thereof by administration of a therapeutically effective amount of PDGF-related protein LP8 or antagonist thereof. | | |

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | | | |
|----|--------------------------|----|--|----|--|----|--------------------------|
| AL | Albania | ES | Spain | LS | Lesotho | SI | Slovenia |
| AM | Armenia | FI | Finland | LT | Lithuania | SK | Slovakia |
| AT | Austria | FR | France | LU | Luxembourg | SN | Senegal |
| AU | Australia | GA | Gabon | LV | Latvia | SZ | Swaziland |
| AZ | Azerbaijan | GB | United Kingdom | MC | Monaco | TD | Chad |
| BA | Bosnia and Herzegovina | GE | Georgia | MD | Republic of Moldova | TG | Togo |
| BB | Barbados | GH | Ghana | MG | Madagascar | TJ | Tajikistan |
| BE | Belgium | GN | Guinea | MK | The former Yugoslav Republic of Macedonia | TM | Turkmenistan |
| BF | Burkina Faso | GR | Greece | | | TR | Turkey |
| BG | Bulgaria | HU | Hungary | ML | Mali | TT | Trinidad and Tobago |
| BJ | Benin | IE | Ireland | MN | Mongolia | UA | Ukraine |
| BR | Brazil | IL | Israel | MR | Mauritania | UG | Uganda |
| BY | Belarus | IS | Iceland | MW | Malawi | US | United States of America |
| CA | Canada | IT | Italy | MX | Mexico | UZ | Uzbekistan |
| CF | Central African Republic | JP | Japan | NE | Niger | VN | Viet Nam |
| CG | Congo | KE | Kenya | NL | Netherlands | YU | Yugoslavia |
| CH | Switzerland | KG | Kyrgyzstan | NO | Norway | ZW | Zimbabwe |
| CI | Côte d'Ivoire | KP | Democratic People's Republic of Korea | NZ | New Zealand | | |
| CM | Cameroon | | | PL | Poland | | |
| CN | China | KR | Republic of Korea | PT | Portugal | | |
| CU | Cuba | KZ | Kazakstan | RO | Romania | | |
| CZ | Czech Republic | LC | Saint Lucia | RU | Russian Federation | | |
| DE | Germany | LI | Liechtenstein | SD | Sudan | | |
| DK | Denmark | LK | Sri Lanka | SE | Sweden | | |
| EE | Estonia | LR | Liberia | SG | Singapore | | |

-1-

PLATELET-DERIVED GROWTH FACTOR RELATED GENE AND PROTEIN

CROSS REFERENCE

This application claims the benefit of U.S. Provisional
5 Application No. 60/127,913 filed April 6, 1999, said
application being entirely incorporated herein by reference.

BACKGROUND OF THE INVENTION

This invention relates to recombinant DNA technology.
10 In particular the invention relates to platelet-derived
growth factor (PDGF) homologs, and to therapeutic and other
uses thereof.

Recently, much attention has been paid to the use of
growth factors to accelerate wound healing, particularly of
15 skin. Growth factors are agents which cause cells to
migrate, differentiate, transform, or mature and divide.
These factors are polypeptides which can be isolated
from a variety of normal and malignant mammalian cell types.
Some growth factors can be produced by genetically-
20 engineered microorganisms such as bacteria (*Escherichia*
coli) and yeasts. See, e.g., Chapters 10 and 11 of Molecular
and Cellular Biology of Wound Repair (1986), incorporated
herein by reference. Included among the growth factors are
epidermal growth factor (EGF), transforming growth factors
25 alpha and beta, fibroblast growth factor (FGF), insulin-like
growth factor (IGF), nerve growth factor (NGF), and
platelet-derived growth factor (PDGF). These molecules are
described in U.S. Pat. No. 4,939,135 to Robertson et al.,
incorporated herein by reference.

-2-

The use of PDGF to accelerate wound healing in skin and connective tissue has been investigated (Antoniades et al., Proc. Natl. Acad. Sci. USA 88:565-569 (1991); Cromack et al., J. Trauma 30:S129-133 (1990); Ross et al., Philos. Trans. R. Soc. Lond. (Biol.) 327:155-169 (1990)). Human platelet-derived growth factor (PDGF) is believed to be the major mitogenic growth factor in serum for connective tissue cells. PDGF has been shown to induce mitogenesis in arterial smooth muscle cells, fibroblast cell lines, and glial cells. See e.g. Deuel et al, J. Biol. Chem., 256(17), 8896-8899 (1981); Heldin et al, J. Cell Physiol., 105, 235 (1980) (brain glial cells); Raines and Ross, J. Biol. Chem., 257, 5154 (1982) (monkey arterial smooth muscle cells). PDGF is also believed to be a chemoattractant for fibroblasts, smooth muscle cells, monocytes, and granulocytes. Because of its apparent abilities to induce mitogenesis and to attract fibroblasts to the site of wounds, PDGF is thought to have particular potential for therapeutic use in the repair of injured, or traumatized, connective tissues.

PDGF was initially described by Ross et al, Proc. Natl. Acad. Sci. USA, 71, 1207-1210 (1974), as a factor found in whole blood serum that is capable of supporting the growth of fibroblasts in culture. PDGF was subsequently isolated from platelets and from serum, with the native unreduced PDGF being identified as a 27-35 kd mw dimeric protein. Reduction of PDGF yields two or more subunits in a molecular weight range of approximately 18 kd and 16 kd molecular weights, respectively, the "A" and "B" subunits. The A chain is approximately 35% homologous to the B chain. The PDGF B

-3-

chain from human platelets comprises a 109 amino acid cleavage product of a 241 amino acid precursor polypeptide. Johnsson et al, EMBO Journal, 3(5), 921-928 (1984). PDGF is believed to be biologically active only in dimeric form.

5 Biologically active PDGF dimers can take the form of a PDGF A-B heterodimer, a PDGF B-B homodimer, or a PDGF A-A homodimer. Hannink et al, Mol. Cell. Biol., 6, 1304-1314 (1986). Each monomeric subunit of the biologically active dimer, irrespective of whether it is an A chain or a B
10 chain, contains eight cysteine residues, some of which form interchain disulfide bonds which hold the dimer together. The 109 amino acid sequence (PDGF B.sub.109), identified as being the mature form of PDGF B, has been produced in yeast and other eucaryotic host cell systems.

15 It is an object of the present invention to provide compositions and therapeutic methods for enhancing tissue proliferation and wound healing using a homolog of PDGF, designated herein as LP8.

20 BRIEF SUMMARY OF THE INVENTION

The present invention relates to isolated nucleic acid and protein molecules related to the PDGF family, termed herein "LP8" (also referred to as "VEGFh"). The LP8 sequence (SEQ ID NO:2) disclosed herein was identified from a human
25 source. Having the cloned LP8 gene enables the production of recombinant LP8 protein, and related molecules, the isolation of orthologous genes from other organisms, and/or paralogous genes from the same organism, chromosome mapping studies, and the implementation of large scale screens to

-4-

identify compounds that inhibit the binding of LP8 or related molecule to its cognate receptor, as a means to identify potential pharmaceutical compounds useful for modulating tissue growth. For example, antagonists of LP8
5 and/or inhibitors thereof, are useful in preventing and treating atherosclerosis by virtue of blocking smooth muscle cell growth. The proteins, peptides, and analogs thereof, described herein are also useful therapeutic agents for stimulating tissue growth, for example, as medicaments to
10 promote wound healing.

In one embodiment the present invention relates to LP8 protein (SEQ ID NO:2), and analogs thereof that are structurally and functionally related to SEQ ID NO:2.

In another embodiment the present invention relates to
15 a modified, soluble LP8 protein comprising a carboxyl end fragment of SEQ ID NO:2.

In another embodiment the present invention relates to an isolated nucleic acid molecule encoding LP8 protein, and related proteins described herein.

20 In another embodiment, the invention relates to a nucleic acid molecule comprising the nucleotide sequence identified as SEQ ID NO:1, and/or residues 276 through 1310 of SEQ ID NO:1.

In another embodiment, the present invention relates to
25 a nucleic acid that encodes SEQ ID NO:2.

In another embodiment, the present invention relates to a nucleic acid that hybridizes to residues 276 through 1310 of SEQ ID NO:1 under high stringency conditions, said

-5-

nucleic acid encoding a protein that is capable of inducing mitogenesis in vivo or in vitro.

In yet another embodiment, the present invention relates to a recombinant DNA vector that incorporates the LP8 gene (residues 276 through 1310 of SEQ ID NO:1) in operable-linkage to gene expression sequences, enabling said gene to be transcribed and translated in a host cell.

In still another embodiment the present invention relates to host cells that have been transformed or transfected with the cloned LP8 gene such that said gene is expressed in the host cell.

In another embodiment, the present invention relates to a method for promoting wound healing by the administration of a therapeutically-effective amount of LP8.

In another embodiment the present invention relates to a method for preventing, inhibiting, or treating atherosclerosis.

In yet another embodiment, the present invention relates to a pharmaceutical formulation comprising as an active ingredient a therapeutically effective amount of an LP8, associated with one or more pharmaceutically acceptable carriers, excipients, or diluents thereof.

DETAILED DESCRIPTION OF THE INVENTION

25

Definitions

The term "analog" or "functional analog" refers to a modified form of LP8 in which at least one amino acid substitution and/or deletion has been made in SEQ ID NO:2 or

-6-

fragment thereof such that said analog retains substantially the same biological activity as the unmodified LP8 or fragment thereof in vivo and/or in vitro.

The terms "complementary" or "complementarity" as used
5 herein refer to the capacity of purine and pyrimidine nucleotides to associate through hydrogen bonding to form double stranded nucleic acid molecules. The following base pairs are related by complementarity: guanine and cytosine; adenine and thymine; and adenine and uracil. As used herein,
10 "complementary" means that the aforementioned relationship applies to substantially all base pairs comprising two single-stranded nucleic acid molecules over the entire length of said molecules. "Partially complementary" refers to the aforementioned relationship in which one of two
15 single-stranded nucleic acid molecules is shorter in length than the other such that a portion of one of the molecules remains single-stranded.

The term "conservative substitution" or "conservative amino acid substitution" refers to a
20 replacement of one or more amino acid residue(s) in a parent protein as stipulated by Table 1.

"Fragment thereof" refers to a fragment, piece, or sub-region of a nucleic acid or protein molecule, such that said fragment comprises 5 or more amino acids, or 10 or more
25 nucleotides that are contiguous in the parent protein or nucleic acid molecule.

"Functional fragment," as used herein, refers to an isolated sub-region, or fragment of a protein, or sequence of amino acids that, for example, comprises a

-7-

functionally distinct region such as an active site for an enzyme, or a binding site for a substrate, or a binding site for a receptor. Functional fragments may be produced by subcloning methods, or as the natural products of
5 alternative splicing mechanisms.

"Functionally-related" as used herein is applied to proteins or peptides that are predicted to be functionally similar or identical to a progenitor molecule, for example, LP8 or functional fragment thereof.

10 Functionally related molecules can be identified based on chemical and physical similarities in amino acid composition and sequence.

"Host cell" refers to any eucaryotic or procaryotic cell that is suitable for propagating and/or
15 expressing a cloned gene contained on a vector that is introduced into said host cell by, for example, transformation or transfection, or the like.

LP8 (also referred to as "VEGFh") refers to a nucleic acid, or gene, or cDNA (e.g. SEQ ID NO:1 and/or
20 coding region therein) and to a protein (SEQ ID NO:2 and/or analogs or functional fragments thereof). LP8 is a member of the PDGF family of proteins.

The term "homolog" or "homologous" describes a relationship between different nucleic acid molecules or
25 different protein molecules in which said molecules are related by partial identity or similarity at one or more regions within said molecules.

The term "hybridization" as used herein refers to a process in which a single-stranded nucleic acid molecule

-8-

joins with a complementary strand through nucleotide base pairing. "Selective hybridization" refers to hybridization under conditions of high stringency. The degree of hybridization depends upon, for example, the degree of
5 homology or relatedness, the stringency of hybridization, and the length of hybridizing strands.

"Isolated nucleic acid compound" refers to any specific RNA or DNA molecule, however constructed or synthesized or isolated, which is locationally distinct from
10 its natural location, and which is substantially free of other larger or smaller nucleic acid compounds.

A "nucleic acid probe" or "probe" as used herein is a labeled nucleic acid compound which hybridizes with another nucleic acid compound. "Nucleic acid probe" means a
15 single stranded nucleic acid sequence that will combine with a complementary or partially complementary single stranded target nucleic acid sequence to form a double-stranded molecule. A nucleic acid probe may be an oligonucleotide or a nucleotide polymer. A probe will usually contain a
20 detectable moiety which may be attached to the end(s) of the probe or be internal to the sequence of the probe.

The term "orthologue" or "orthologous" refers to two or more genes or proteins from different organisms that exhibit sequence homology.

25 The term "paralogue" or "paralogous" refers to two or more genes or proteins within a single organism that exhibit sequence homology.

The term "plasmid" refers to an extrachromosomal genetic element. The plasmids disclosed herein are

-9-

commercially available, publicly available on an unrestricted basis, or can be constructed from readily available plasmids in accordance with published procedures.

A "primer" is a nucleic acid fragment which
5 functions as an initiating substrate for enzymatic or synthetic elongation of, for example, a nucleic acid molecule.

The term "promoter" refers to a nucleic acid sequence that directs transcription, for example, of DNA to
10 RNA. An inducible promoter is one that is regulatable by environmental signals, such as carbon source, heat, or metal ions, for example. A constitutive promoter generally operates at a constant level and is not regulatable.

"Recombinant DNA cloning vector" as used herein
15 refers to any autonomously replicating agent, including, but not limited to, plasmids and phages, comprising a DNA molecule to which one or more additional DNA segments can or have been incorporated.

The term "recombinant DNA expression vector" or
20 "expression vector" as used herein refers to any recombinant DNA cloning vector, for example a plasmid or phage, in which a promoter and other regulatory elements are present thereby enabling transcription of an inserted DNA, which may encode a protein.

25 The term "stringency" refers to hybridization conditions. High stringency conditions disfavor non-homologous base pairing. Low stringency conditions have the opposite effect. Stringency may be altered, for example, by temperature and salt concentration.

-10-

"Low stringency" conditions comprise, for example, a temperature of about 37° C or less, a formamide concentration of less than about 50%, and a moderate to low salt (SSC) concentration; or, alternatively, a temperature
5 of about 50° C or less, and a moderate to high salt (SSPE) concentration, for example 1M NaCl.

"High stringency" conditions comprise, for example, a temperature of about 42° C or less, a formamide concentration of less than about 20%, and a low salt (SSC)
10 concentration; or, alternatively, a temperature of about 65° C, or less, and a low salt (SSPE) concentration. For example, high stringency conditions comprise hybridization in 0.5 M NaHPO₄, 7% sodium dodecyl sulfate (SDS), 1 mM EDTA at 65°C (Ausubel, F.M. et al. Current Protocols in
15 Molecular Biology, Vol. I, 1989; Green Inc. New York, at 2.10.3).

"SSC" comprises a hybridization and wash solution. A stock 20X SSC solution contains 3M sodium chloride, 0.3M sodium citrate, pH 7.0.

20 "SSPE" comprises a hybridization and wash solution. A 1X SSPE solution contains 180 mM NaCl, 9mM Na₂HPO₄, 0.9 mM NaH₂PO₄ and 1 mM EDTA, pH 7.4.

"Substantially pure," used in reference to a peptide or protein, means separation from other cellular and
25 non-cellular molecules, including other protein molecules. A substantially pure preparation would be about at least 85% pure; preferably about at least 95% pure. A "substantially pure" protein can be prepared by a variety of techniques,

-11-

well known to the skilled artisan, including, for example, the IMAC protein purification method.

"Treating" as used herein describes the management and care of a patient for the purpose of combating a disease, condition, or disorder and includes the administration of a protein of the present invention to prevent the onset of the symptoms or complications, alleviating the symptoms or complications, or eliminating the disease, condition, or disorder. Treating as used herein includes the administration of the protein for cosmetic purposes.

The term "vector" as used herein refers to a nucleic acid compound used for introducing exogenous or endogenous DNA into host cells. A vector comprises a nucleotide sequence which may encode one or more protein molecules. Plasmids, cosmids, viruses, and bacteriophages, in the natural state or which have undergone recombinant engineering, are examples of commonly used vectors.

The various restriction enzymes disclosed and described herein are commercially available and the manner of use of said enzymes including reaction conditions, cofactors, and other requirements for activity are well known to one of ordinary skill in the art. Reaction conditions for particular enzymes were carried out according to the manufacturer's recommendation.

The LP8 gene encodes a protein that is related to the PDGF family of proteins. The LP8 cDNA comprises a DNA sequence specified herein by SEQ ID NO:1, the coding region being defined by residues 276 through 1310 of SEQ ID NO:1.

-12-

Those skilled in the art will recognize that owing to the degeneracy of the genetic code, numerous "silent" substitutions of nucleotide base pairs could be introduced into the coding sequence identified as SEQ ID NO:1 without
5 altering the identity of the encoded amino acid(s) or protein product. All such substitutions are intended to be within the scope of the invention.

The LP8 gene is expressed prominently in epithelial cells and in smooth muscle cells. As demonstrated below, LP8
10 protein stimulates the proliferation of both of these cell types and therefore appears to be a mitogenic factor for these cell types.

Also contemplated by the present invention are LP8-related proteins and analogs, functional fragments of LP8 and analogs thereof. The LP8 protein may be membrane-bound
15 in vivo. For example, expression of a LP8 DNA expression vector in 293 T cells or CHO cells showed LP8 on the cell membrane of transfected cells as detected by FACS staining using an anti-LP8 serum, or anti-FLAG to a FLAG-tagged LP8.

20 A secreted form of LP8 can be produced by removing a portion of the sequence at the amino terminus and fusing therefore, any suitable signal peptide to facilitate secretion from an expression host cell. For example, residues from about 1 through about 22 of SEQ ID NO:2, or residues from about 1
25 through about 15 of SEQ ID NO:2 can be removed and replaced with the kappa light chain signal sequence, or any other suitable signal peptide, for example the protrypsin signal peptide or other signal peptide. Functional fragments comprising sub-regions of LP8 (SEQ ID NO:2) are also

-13-

contemplated by the present invention. Exemplary functional fragments comprise from about residues 1 through about 29 of SEQ ID NO:2 and from about residues 30 through about 80 of SEQ ID NO:2. These subregions define a kinase domain
5 receptor (KDR) binding site.

Other functional fragments are conveniently identified as fragments of LP8 protein that retain mitogenic activity in vivo or in vitro.

Amino acid substitutions can be made in the LP8
10 molecule in accordance with the following Table. Modifications of LP8 peptides made in accordance with the Table are generally expected to retain the biological activity of LP8 based on art recognized substitutability of certain amino acids (See e.g. M. Dayhoff, In Atlas of
15 Protein Sequence and Structure, Vol. 5, Supp. 3, pgs 345-352, 1978). Functionality of analogs is easily tested in an assay that measures endothelial cell mitogenic activity, for example.

-14-

| <u>ORIGINAL RESIDUE</u> | <u>EXEMPLARY SUBSTITUTIONS</u> |
|-------------------------|--------------------------------|
| ALA | SER, THR |
| ARG | LYS |
| ASN | HIS, SER |
| ASP | GLU, ASN |
| CYS | SER |
| GLN | ASN, HIS |
| GLU | ASP, GLU |
| GLY | ALA, SER |
| HIS | ASN, GLN |
| ILE | LEU, VAL, THR |
| LEU | ILE, VAL |
| LYS | ARG, GLN, GLU, THR |
| MET | LEU, ILE, VAL |
| PHE | LEU, TYR |
| SER | THR, ALA, ASN |
| THR | SER, ALA |
| TRP | ARG, SER |
| TYR | PHE |
| VAL | ILE, LEU, ALA |
| PRO | ALA |

Functionally related proteins and peptides

Structurally-related analogs having biological
5 activities that are similar or identical to LP8, for
example, the ability to induce mitogenesis, in vivo or in
vitro, are also contemplated by the present invention. Said

-15-

analogs, while being functionally related, comprise amino acid sequences that differ in one or more positions from SEQ ID NO:2. Functional analogs of LP8 can be generated by deletion, insertion, inversion, and/or substitution of one or more amino acid residues in said LP8. Substitution analogs can generally be made by solid phase or recombinant techniques in which, for example, single or multiple conservative amino acid substitutions are made, for example, according to Table 1. Generally, in the case of multiple substitutions, it is preferred that less than ten residues be changed in any given molecule, most preferably between one to five residues are changed in any given molecule, such that about between 90% to 99% of residues are identical with the sequence of SEQ ID NO:2; alternatively, such that about between 95% to 99% of residues are identical with SEQ ID NO:2.

Fragments of proteins

One embodiment of the instant invention provides fragments of the LP8 proteins and analogs that may or may not be biologically active. Such fragments are useful, for example, as antigens for producing an antibody to said proteins.

Fragments of the LP8 proteins and analogs may be generated by any number of suitable techniques, including chemical synthesis of any portion of SEQ ID NO:2, proteolytic digestion of SEQ ID NO:2, or most preferably, by recombinant DNA mutagenesis techniques, well known to the skilled artisan. See. e.g. K. Struhl, "Reverse biochemistry:

-16-

Methods and applications for synthesizing yeast proteins *in vitro*," *Meth. Enzymol.* 194, 520-535. For example, in a preferred method, a nested set of deletion mutations are introduced into a nucleic acid sequence encoding LP8 (e.g. residues 276 through 1310 of SEQ ID NO:1) such that varying amounts of the protein coding region are deleted, either from the amino terminal end, or from the carboxyl end of the protein molecule. This method can also be used to create internal fragments of the intact protein in which both the carboxyl and amino terminal ends are removed. Several appropriate nucleases can be used to create such deletions, for example *Bal31*, or in the case of a single stranded nucleic acid molecule, mung bean nuclease. For simplicity, it is preferred that the LP8 gene be cloned into a single-stranded cloning vector, such as bacteriophage M13, or equivalent. If desired, the resulting gene deletion fragments can be subcloned into any suitable vector for propagation and expression of said fragments in any suitable host cell.

Functional fragments of the proteins disclosed herein may be produced as described above, preferably using cloning techniques to engineer smaller versions of the intact gene, lacking sequence from the 5' end, the 3' end, from both ends, or from an internal site. Fragments may be tested for biological activity using any suitable assay, for example, the ability of a protein fragment to induce mitogenesis, *in vivo* or *in vitro*.

-17-

Gene Isolation Procedures

Those skilled in the art will recognize that the LP8 gene could be obtained by a plurality of recombinant DNA techniques including, for example, hybridization, polymerase chain reaction (PCR) amplification, or de novo DNA synthesis. (See e.g., T. Maniatis et al. Molecular Cloning: A Laboratory Manual, 2d Ed. Chap. 14 (1989)).

Methods for constructing cDNA libraries in a suitable vector such as a plasmid or phage for propagation in procaryotic or eucaryotic cells are well known to those skilled in the art. [See e.g. Maniatis et al. *Supra*]. Suitable cloning vectors are well known and are widely available.

The LP8 gene, or fragment thereof, can be isolated from a tissue in which said gene is expressed, for example, placenta. In one method, mRNA is isolated, and first strand cDNA synthesis is carried out. A second round of DNA synthesis can be carried out for the production of the second strand. If desired, the double-stranded cDNA can be cloned into any suitable vector, for example, a plasmid, thereby forming a cDNA library. Oligonucleotide primers targeted to any suitable region of SEQ ID NO:1 can be used for PCR amplification of LP8. See e.g. PCR Protocols: A Guide to Method and Application, Ed. M. Innis et al., Academic Press (1990). The PCR amplification comprises template DNA, suitable enzymes, primers, and buffers, and is conveniently carried out in a DNA Thermal Cycler (Perkin Elmer Cetus, Norwalk, CT). A positive result is determined

-18-

by detecting an appropriately-sized DNA fragment following agarose gel electrophoresis.

Protein Production Methods

5 One embodiment of the present invention relates to the substantially purified protein encoded by the LP8 gene.

 Skilled artisans will recognize that the proteins of the present invention can be synthesized by a number of different methods, such as chemical methods well known in
10 the art, including solid phase peptide synthesis or recombinant methods. Both methods are described in U.S. Patent 4,617,149, incorporated herein by reference.

 The principles of solid phase chemical synthesis of polypeptides are well known in the art and may be found
15 in general texts in the area. See, e.g., H. Dugas and C. Penney, Bioorganic Chemistry (1981) Springer-Verlag, New York, 54-92. For example, peptides may be synthesized by solid-phase methodology utilizing an Applied Biosystems 430A peptide synthesizer (Applied Biosystems, Foster City, CA)
20 and synthesis cycles supplied by Applied Biosystems.

 The proteins of the present invention can also be produced by recombinant DNA methods using the cloned LP8 gene. Recombinant methods are preferred if a high yield is desired. Expression of the cloned gene can be carried out in
25 a variety of suitable host cells, well known to those skilled in the art. For this purpose, the LP8 gene is introduced into a host cell by any suitable means, well known to those skilled in the art. While chromosomal integration of the cloned gene is within the scope of the

-19-

present invention, it is preferred that the gene be cloned into a suitable extra-chromosomally maintained expression vector so that the coding region of the LP8 gene is operably-linked to a constitutive or inducible promoter.

5 The basic steps in the recombinant production of the LP8 protein are:

- a) constructing a natural, synthetic or semi-synthetic DNA encoding LP8 protein;
- 10 b) integrating said DNA into an expression vector in a manner suitable for expressing the LP8 protein, either alone or as a fusion protein;
- 15 c) transforming or otherwise introducing said vector into an appropriate eucaryotic or prokaryotic host cell forming a recombinant host cell,
- 20 d) culturing said recombinant host cell in a manner to express the LP8 protein; and
- 25 e) recovering and substantially purifying the LP8 protein by any suitable means, well known to those skilled in the art.

-20-

Expressing Recombinant LP8 Protein in Procaryotic and
Eucaryotic Host Cells

Procaryotes may be employed in the production of recombinant LP8 protein. For example, the *Escherichia coli* K12 strain 294 (ATCC No. 31446) is particularly useful for the prokaryotic expression of foreign proteins. Other strains of *E. coli*, bacilli such as *Bacillus subtilis*, enterobacteriaceae such as *Salmonella typhimurium* or *Serratia marcescans*, various *Pseudomonas* species and other bacteria, such as *Streptomyces*, may also be employed as host cells in the cloning and expression of the recombinant proteins of this invention.

Promoter sequences suitable for driving the expression of genes in procaryotes include b⁻-lactamase [e.g. vector pGX2907, ATCC 39344, contains a replicon and b⁻-lactamase gene], lactose systems [Chang et al., *Nature* (London), 275:615 (1978); Goeddel et al., *Nature* (London), 281:544 (1979)], alkaline phosphatase, and the tryptophan (trp) promoter system [vector pATH1 (ATCC 37695)], which is designed to facilitate expression of an open reading frame as a trpE fusion protein under the control of the trp promoter. Hybrid promoters such as the tac promoter (isolatable from plasmid pDR540, ATCC-37282) are also suitable. Still other bacterial promoters, whose nucleotide sequences are generally known, may be ligated to DNA encoding the protein of the instant invention, using linkers or adapters to supply any required restriction sites. Promoters for use in bacterial systems also will contain a Shine-Dalgarno sequence operably-linked to the DNA encoding

-21-

the desired polypeptides. These examples are illustrative rather than limiting.

The proteins of this invention may be synthesized either by direct expression or as a fusion protein comprising the protein of interest as a translational fusion with another protein or peptide which may be removable by enzymatic or chemical cleavage. It is often observed in the production of certain peptides in recombinant systems that expression as a fusion protein prolongs the life span, increases the yield of the desired peptide, or provides a convenient means of purifying the protein. This is particularly relevant when expressing mammalian proteins in procaryotic hosts. A variety of peptidases (e.g. enterokinase and thrombin) which cleave a polypeptide at specific sites or digest the peptides from the amino or carboxy termini (e.g. diaminopeptidase) of the peptide chain are known. Furthermore, particular chemicals (e.g. cyanogen bromide) will cleave a polypeptide chain at specific sites. The skilled artisan will appreciate the modifications necessary to the amino acid sequence (and synthetic or semi-synthetic coding sequence if recombinant means are employed) to incorporate site-specific internal cleavage sites. See e.g., P. Carter, "Site Specific Proteolysis of Fusion Proteins", Chapter 13, in Protein Purification: From Molecular Mechanisms to Large Scale Processes, American Chemical Society, Washington, D.C. (1990).

In addition to procaryotes, a variety of amphibian expression systems such as frog oocytes, and mammalian cell systems can be used. The choice of a particular host cell

-22-

depends to some extent on the particular expression vector used. Exemplary mammalian host cells suitable for use in the present invention include HepG-2 (ATCC HB 8065), CV-1 (ATCC CCL 70), LC-MK₂ (ATCC CCL 7.1), 3T3 (ATCC CCL 92),
5 CHO-K1 (ATCC CCL 61), HeLa (ATCC CCL 2), RPMI8226 (ATCC CCL 155), H4IIEC3 (ATCC CCL 1600), C127I (ATCC CCL 1616), HS-Sultan (ATCC CCL 1484), and BHK-21 (ATCC CCL 10), for example.

A wide variety of vectors are suitable for
10 transforming mammalian host cells. For example, the pSV2-type vectors comprise segments of the simian virus 40 (SV40) genome required for transcription and polyadenylation. A large number of plasmid pSV2-type vectors have been constructed, such as pSV2-gpt, pSV2-neo, pSV2-dhfr, pSV2-
15 hyg, and pSV2-b-globin, in which the SV40 promoter drives transcription of an inserted gene. These vectors are widely available from sources such as the American Type Culture Collection (ATCC), 12301 Parklawn Drive, Rockville, Maryland, 20852, or the Northern Regional Research
20 Laboratory (NRRL), 1815 N. University Street, Peoria, Illinois, 61604.

Promoters suitable for expression in mammalian cells include the SV40 late promoter, promoters from eukaryotic genes, such as, for example, the estrogen-
25 inducible chicken ovalbumin gene, the interferon genes, the glucocorticoid-inducible tyrosine aminotransferase gene, the thymidine kinase gene promoter, and the promoters of the major early and late adenovirus genes and the cytomegalovirus promoter.

-23-

Plasmid pRSVcat (ATCC 37152) comprises portions of a long terminal repeat of the Rous Sarcoma virus, a virus known to infect chickens and other host cells. This long terminal repeat contains a promoter which is suitable for use in the vectors of this invention. H. Gorman et al., *Proc. Nat. Acad. Sci. (USA)*, 79, 6777 (1982). The plasmid pMSVi (NRRL B-15929) comprises the long terminal repeats of the Murine Sarcoma virus, a virus known to infect mouse and other host cells. The mouse metallothionein promoter has also been well characterized for use in eukaryotic host cells and is suitable for use in the present invention. This promoter is present in the plasmid pdBPV-MMTneo (ATCC 37224) which can serve as the starting material for the construction of other plasmids of the present invention.

Transfection of mammalian cells with vectors can be performed by a plurality of well known processes including, but not limited to, protoplast fusion, calcium phosphate co-precipitation, electroporation and the like. See, e.g., Maniatis et al., *supra*.

Some viruses also make appropriate vectors. Examples include the adenoviruses, the adeno-associated viruses, the vaccinia virus, the herpes viruses, the baculoviruses, and the rous sarcoma virus, as described in U.S. Patent 4,775,624, incorporated herein by reference.

Eucaryotic microorganisms such as yeast and other fungi are also suitable host cells. The yeast *Saccharomyces cerevisiae* is the preferred eucaryotic microorganism. Other yeasts such as *Kluyveromyces lactis* and *Pichia pastoris* are also suitable. For expression in *Saccharomyces*, the plasmid

-24-

YRp7 (ATCC-40053), for example, may be used. See, e.g., L. Stinchcomb et al., *Nature*, 282, 39 (1979); J. Kingsman et al., *Gene*, 7, 141 (1979); S. Tschemper et al., *Gene*, 10, 157 (1980). Plasmid YRp7 contains the TRP1 gene which provides
5 a selectable marker for use in a trp1 auxotrophic mutant.

Purification of Recombinantly-Produced LP8 Protein

An expression vector carrying the cloned LP8 gene is transformed or transfected into a suitable host cell
10 using standard methods. Cells that contain the vector are propagated under conditions suitable for expression of the recombinant LP8 protein. For Example, if the recombinant gene has been placed under the control of an inducible promoter, suitable growth conditions would incorporate the
15 appropriate inducer. The recombinantly-produced protein may be purified from cellular extracts of transformed cells by any suitable means.

In a preferred process for protein purification, the LP8 gene is modified at the 5' end to incorporate
20 several histidine residues at the amino terminus of the LP8 protein. This "histidine tag" enables a single-step protein purification method referred to as "immobilized metal ion affinity chromatography" (IMAC), essentially as described in U.S. Patent 4,569,794, which hereby is incorporated by
25 reference. The IMAC method enables rapid isolation of substantially pure recombinant LP8 protein starting from a crude extract of cells that express a modified recombinant protein, as described above.

-25-

Production of Antibodies

The proteins of this invention and fragments thereof may be used in the production of antibodies. The term "antibody" as used herein describes antibodies, fragments of antibodies (such as, but not limited, to Fab, Fab', Fab₂', and Fv fragments), and chimeric, humanized, veneered, resurfaced, or CDR-grafted antibodies capable of binding antigens of a similar nature as the parent antibody molecule from which they are derived. The instant invention also encompasses single chain polypeptide binding molecules.

The production of antibodies, both monoclonal and polyclonal, in animals, especially mice, is well known in the art. See, e.g., C. Milstein, Handbook of Experimental Immunology, (Blackwell Scientific Pub., 1986); J. Goding, Monoclonal Antibodies: Principles and Practice, (Academic Press, 1983). For the production of monoclonal antibodies the basic process begins with injecting a mouse, or other suitable animal, with an immunogen. The mouse is subsequently sacrificed and cells taken from its spleen are fused with myeloma cells, resulting in a hybridoma that reproduces *in vitro*. The population of hybridomas is screened to isolate individual clones, each of which secretes a single antibody species, specific for the immunogen. Each antibody obtained in this way is the clonal product of a single B cell.

Chimeric antibodies are described in U.S. Patent No. 4,816,567, the entire contents of which is herein incorporated by reference. This reference discloses methods and vectors for the preparation of chimeric antibodies. An

-26-

alternative approach is provided in U.S. Patent No. 4,816,397, the entire contents of which is herein incorporated by reference. This patent teaches co-expression of the heavy and light chains of an antibody in
5 the same host cell.

The approach of U.S. Patent 4,816,397 has been further refined in European Patent Publication No. 0 239 400. The teachings of this European patent publication are a preferred format for genetic engineering of monoclonal
10 antibodies. In this technology the complementarity determining regions (CDRs) of a human antibody are replaced with the CDRs of a murine monoclonal antibody, thereby converting the specificity of the human antibody to the specificity of a murine antibody.

15 Single chain antibodies and libraries thereof are yet another variety of genetically engineered antibody technology that is well known in the art. (See, e.g. R.E. Bird, et al., *Science* 242:423-426 (1988); PCT Publication Nos. WO 88/01649, WO 90/14430, and WO 91/10737. Single chain
20 antibody technology involves covalently joining the binding regions of heavy and light chains to generate a single polypeptide chain. The binding specificity of the intact antibody molecule is thereby reproduced on a single polypeptide chain.

25 The antibodies contemplated by this invention are useful in diagnostics, therapeutics or in diagnostic/therapeutic combinations.

The proteins of this invention or suitable fragments thereof can be used to generate polyclonal or monoclonal

-27-

antibodies, and various inter-species hybrids, or humanized antibodies, or antibody fragments, or single-chain antibodies. The techniques for producing antibodies are well known to skilled artisans. (See e.g. A.M. Campbell,

5 Monoclonal Antibody Technology: Laboratory Techniques in Biochemistry and Molecular Biology, Elsevier Science Publishers, Amsterdam (1984); Kohler and Milstein, *Nature* 256, 495-497 (1975); Monoclonal Antibodies: Principles & Applications Ed. J.R.Birch & E.S. Lennox, Wiley-Liss, 1995.

10 A protein used as an immunogen may be modified or administered in an adjuvant, by subcutaneous or intraperitoneal injection into, for example, a mouse or a rabbit. For the production of monoclonal antibodies, spleen cells from immunized animals are removed, fused with myeloma
15 cells, such as SP2/0-Ag14 cells, and allowed to become monoclonal antibody producing hybridoma cells in the manner known to the skilled artisan. Hybridomas that secrete a desired antibody molecule can be screened by a variety of well known methods, for example ELISA assay, western blot
20 analysis, or radioimmunoassay (Lutz et al. *Exp. Cell Res.* 175, 109-124 (1988); Monoclonal Antibodies: Principles & Applications Ed. J.R.Birch & E.S. Lennox, Wiley-Liss, 1995).

For some applications labeled antibodies are desirable. Procedures for labeling antibody molecules are widely known,
25 including for example, the use of radioisotopes, affinity labels, such as biotin or avidin, enzymatic labels, for example horseradish peroxidase, and fluorescent labels, such as FITC or rhodamine (See e.g. Enzyme-Mediated Immunoassay, Ed. T. Ngo, H. Lenhoff, Plenum Press 1985; Principles of

-28-

Immunology and Immunodiagnostics, R.M. Aloisi, Lea & Febiger, 1988).

Labeled antibodies are useful for a variety of diagnostic applications. In one embodiment the present invention relates to the use of labeled antibodies to detect the presence of LP8. Alternatively, the antibodies could be used in a screen to identify potential modulators of LP8. For example, in a competitive displacement assay, the antibody or compound to be tested is labeled by any suitable method. Competitive displacement of an antibody from an antibody-antigen complex by a test compound such that a test compound-antigen complex is formed provides a method for identifying compounds that bind LP8.

Other embodiments of the present invention comprise isolated nucleic acid sequences that encode SEQ ID NO:2, or related nucleic acids that are at least about 75% identical to the coding region of SEQ ID NO:1, or to their complementary sequence, or nucleic acids that hybridize to the coding region of SEQ ID NO:1 under high stringency conditions and encode a protein that has mitogenic activity, or nucleic acid that hybridize to the coding region of SEQ ID NO:1 under high stringency conditions and encode a protein that is at least about 75% identical with SEQ ID NO:2; alternatively, a protein that is at least about 85% identical with SEQ ID NO:2; preferably, a protein that is at least about 90 to 95% identical with SEQ ID NO:2; and most preferably, a protein that is at least 95% identical with SEQ ID NO:2. The percent identity between nucleic acids or proteins is determined by any suitable comparison algorithm,

-29-

well known to the skilled artisan. By percent identity is meant the number of residues that are identical between optimally aligned nucleic acids (or proteins), divided by the total length (including gaps) of the shortest sequence of the pair or group being compared. Nucleic acid or protein sequences are optimally aligned to achieve the greatest degree of similarity, allowing for gaps, using any suitable algorithm, for example, a dynamic programming algorithm (See e.g. Smith and Waterman, J. Mol. Biol. 147, 195 (1985), BLASTA (Altschul et al. J. Mol. Biol. 215, 403 (1990); or FASTA (Lipman & Pearson, Science, 227, 1435 (1985), herein incorporated by reference. Such alignments are carried out with the parameters set to maximize the alignment score obtained for a pair of sequences being compared.

The LP8 cDNA (viz. SEQ ID NO:1) and related nucleic acid molecules that encode SEQ ID NO:2, or functional fragments thereof, or analogs, may be produced by chemical synthetic methods. The synthesis of nucleic acids is well known in the art. See, e.g., E.L. Brown, R. Belagaje, M.J. Ryan, and H.G. Khorana, *Methods in Enzymology*, 68:109-151 (1979). Fragments of the DNA sequence corresponding to the LP8 gene could be generated using a conventional DNA synthesizing apparatus, such as the Applied Biosystems Model 380A or 380B DNA synthesizers (Applied Biosystems, Inc., 850 Lincoln Center Drive, Foster City, CA 94404) using phosphoramidite chemistry, thereafter ligating the fragments so as to reconstitute the entire gene. Alternatively, phosphotriester chemistry may be employed to synthesize the nucleic acids of this invention.

-30-

(See, e.g., M.J. Gait, ed., Oligonucleotide Synthesis, A Practical Approach, (1984)).

In an alternative methodology, namely PCR, the DNA sequences disclosed and described herein, comprising, 5 for example, a portion or all of SEQ ID NO:1 can be produced from a plurality of starting materials. For example, starting with a cDNA preparation (e.g. cDNA library) derived from a tissue that expresses the LP8 gene, suitable oligonucleotide primers complementary to SEQ ID NO:1 or to 10 any sub-region therein, are prepared as described in U.S. Patent No. 4,889,818, hereby incorporated by reference. Other suitable protocols for the PCR are disclosed in PCR Protocols: A Guide to Method and Applications, Ed. Michael A. Innis et al., Academic Press, Inc. (1990). Using PCR, any 15 region of the LP8 gene can be targeted for amplification such that full or partial length gene sequences may be produced.

The ribonucleic acids of the present invention may be prepared using polynucleotide synthetic methods discussed 20 *supra*, or they may be prepared enzymatically, for example, using RNA polymerase to transcribe a LP8 DNA template.

The most preferred systems for preparing the ribonucleic acids of the present invention employ the RNA polymerase from the bacteriophage T7 or the bacteriophage 25 SP6. These RNA polymerases are highly specific, requiring the insertion of bacteriophage-specific sequences at the 5' end of the template to be transcribed. See, Maniatis et al., *supra*.

-31-

This invention also provides nucleic acids, RNA or DNA, that are complementary to the coding region of SEQ ID NO:1, or fragment thereof.

Nucleic Acid Probes

5 The present invention also provides probes and primers useful for a variety of molecular biology techniques including, for example, hybridization screens of genomic, subgenomic, or cDNA libraries, as well as hybridization against nucleic acids derived from cell lines or tissues
10 that originate from drug-resistant tumors. Such hybridization screens are useful as methods to identify homologous and/or functionally related sequences from the same or other organisms. A nucleic acid compound comprising SEQ ID NO:1, or a complementary sequence thereof, or a
15 fragment thereof, which is at least 14 base pairs in length, and which will selectively hybridize to human DNA or mRNA encoding LP8 protein or fragment thereof, or a functionally related protein, is provided. Preferably, the 14 or more base pair compound is DNA. See e.g. B. Wallace and G.
20 Miyada, "Oligonucleotide Probes for the Screening of Recombinant DNA Libraries," In *Meth. Enzym.*, 152, 432-442, Academic Press (1987).

 Probes and primers can be prepared by enzymatic or recombinant methods, well known to those skilled in the art
25 (See e.g. Sambrook et al. *supra*). A probe may be a single stranded nucleic acid sequence which is complementary in some particular degree to a nucleic acid sequence sought to be detected ("target sequence"). A probe may be labeled with a detectable moiety such as a radio-isotope, antigen, or

-32-

chemiluminescent moiety. A description of the use of nucleic acid hybridization as a procedure for the detection of particular nucleic acid sequences is described in U.S. Patent No. 4,851,330 to Kohne, entitled "Method for
5 Detection, Identification and Quantitation of Non-Viral Organisms."

Having the DNA sequence of the present invention allows preparation of relatively short DNA (or RNA) sequences having the ability to specifically hybridize to gene
10 sequences disclosed herein. In these aspects, nucleic acid probes of an appropriate length are prepared. The ability of such nucleic acid probes to specifically hybridize to a polynucleotide encoding a LP8 gene or related sequence lends particular utility in a variety of embodiments. Most
15 importantly, the probes may be used in a variety of assays for detecting the presence of complementary sequences in a given sample.

In certain embodiments, it is advantageous to use oligonucleotide primers. The sequence of such primers is
20 designed using a polynucleotide of the present invention for use in detecting, amplifying or mutating a defined segment of a gene or polynucleotide that encodes a LP8 polypeptide using PCR technology.

Preferred nucleic acid sequences employed for
25 hybridization studies, or assays, include probe molecules that are complementary to at least an about 14 to an about 70-nucleotide long stretch of a polynucleotide that encodes a LP8 polypeptide, such as the nucleotide base sequences designated as SEQ ID NO:1. A

-33-

length of at least 14 nucleotides helps to ensure that the fragment is of sufficient length to form a duplex molecule that is both stable and selective. Molecules having complementary sequences over stretches greater than 14 bases
5 in length are generally preferred, though in order to increase stability and selectivity of the hybrid. One will generally prefer to design nucleic acid molecules having gene-complementary stretches of 25 to 40 nucleotides, 55 to 70 nucleotides, or even longer where desired. Such fragments
10 may be readily prepared by, for example, directly synthesizing the fragment by chemical means, by application of nucleic acid reproduction technology, such as the PCR TM technology of U.S. Pat. No. 4,603,102, herein incorporated by reference, or by excising selected DNA fragments from
15 recombinant plasmids containing appropriate inserts and suitable restriction enzyme sites.

The following guidelines are useful for designing probes with desirable characteristics. The extent and specificity of hybridization reactions are affected by a
20 number of factors that determine the sensitivity and specificity of a particular probe, whether perfectly complementary to its target or not. The affect of various experimental parameters and conditions are well known to those skilled in the art.

25 First, the stability of the probe:target nucleic acid hybrid should be chosen to be compatible with the assay conditions. This may be accomplished by avoiding long A and T rich sequences, by terminating the hybrids with G:C base pairs and by designing a probe with an appropriate T_m (i.e.

-34-

melting temperature). The melting profile, including the T_m of a hybrid comprising an oligonucleotide and target sequence, may be determined using a Hybridization Protection Assay. The probe should be chosen so that the length and % GC content result in a T_m about 2°-10° C higher than the temperature at which the final assay will be performed. The base composition of the probe is also a significant factor because G-C base pairs exhibit greater thermal stability as compared to A-T base pairs. Thus, hybridization involving complementary nucleic acids of higher G-C content will be more stable at higher temperatures.

The ionic strength and incubation temperature under which a probe will be used should also be taken into account. It is known that hybridization will increase as the ionic strength of the reaction mixture increases, and that the thermal stability of molecular hybrids will increase with increasing ionic strength. On the other hand, chemical reagents such as formamide, urea, DMSO and alcohols, which disrupt hydrogen bonds, increase the stringency of hybridization. Destabilization of hydrogen bonds by such reagents can greatly reduce the T_m . In general, optimal hybridization for synthetic oligonucleotide probes of about 10-50 bases in length occurs approximately 5° C below the melting temperature for a given duplex. Incubation at temperatures below the optimum may allow mismatched base sequences to hybridize and can therefore result in reduced specificity.

The length of the target nucleic acid sequence and, accordingly, the length of the probe sequence can also be

-35-

important. In some cases, there may be several sequences from a particular region, varying in location and length, which will yield probes with the desired hybridization characteristics. In other cases, one sequence may be significantly better than another even though the one sequence differs merely by a single base. Finally, there can be intramolecular and intermolecular hybrids formed within a probe if there is sufficient self-complementarity. Such structures can be avoided through careful probe design.

Computer programs are available to search for this type of interaction.

A probe molecule may be used for hybridizing to a sample suspected of possessing a LP8 or LP8-related nucleotide sequence. The hybridization reaction is carried out under suitable conditions of stringency.

Alternatively, such DNA molecules may be used in a number of techniques including their use as: (1) diagnostic tools to detect polymorphisms in DNA samples from a human or other mammal; (2) means for detecting and isolating homologs of LP8 and related polypeptides from a DNA library potentially containing such sequences; (3) primers for hybridizing to related sequences for the purpose of amplifying those sequences; and (4) primers for altering the native LP8 DNA sequences; as well as other techniques which rely on the similarity of the DNA sequences to those of the LP8 DNA segments herein disclosed.

Once synthesized, oligonucleotide probes may be labeled by any of several well known methods. See e.g. Maniatis et.al., Molecular Cloning (2d ed. 1989). Useful labels

-36-

include radioisotopes, as well as non-radioactive reporting groups. Isotopic labels include H^3 , S^{35} , P^{32} , I^{125} , Cobalt, and C^{14} . Most methods of isotopic labeling involve the use of enzymes and include methods such as nick-translation, end-labeling, second strand synthesis, and reverse transcription. When using radio-labeled probes, hybridization can be detected by autoradiography, scintillation counting, or gamma counting. The detection method selected will depend upon the hybridization conditions and the particular radio isotope used for labeling.

Non-isotopic materials can also be used for labeling, and may be introduced internally into the sequence or at the end of the sequence. Modified nucleotides may be incorporated enzymatically or chemically, and chemical modifications of the probe may be performed during or after synthesis of the probe, for example, by the use of non-nucleotide linker groups. Non-isotopic labels include fluorescent molecules, chemiluminescent molecules, enzymes, cofactors, enzyme substrates, haptens or other ligands. In a preferred embodiment of the invention, the length of an oligonucleotide probe is greater than or equal to about 18 nucleotides and less than or equal to about 50 nucleotides. Labeling of an oligonucleotide of the present invention may be performed enzymatically using [^{32}P]-labeled ATP and the enzyme T4 polynucleotide kinase.

Vectors

Another aspect of the present invention relates to recombinant DNA cloning vectors and expression vectors

-37-

comprising the nucleic acids of the present invention. The preferred nucleic acid vectors are those which comprise DNA. The most preferred recombinant DNA vectors comprise the isolated DNA sequence, defined by residues 276 through 1310 of SEQ ID NO:1.

The skilled artisan understands that choosing the most appropriate cloning vector or expression vector depends upon a number of factors including the availability of restriction enzyme sites, the type of host cell into which the vector is to be transfected or transformed, the purpose of the transfection or transformation (e.g., stable transformation as an extrachromosomal element, or integration into the host chromosome), the presence or absence of readily assayable or selectable markers (e.g., antibiotic resistance and metabolic markers of one type and another), and the number of copies of the gene desired in the host cell.

Vectors suitable to carry the nucleic acids of the present invention comprise RNA viruses, DNA viruses, lytic bacteriophages, lysogenic bacteriophages, stable bacteriophages, plasmids, viroids, and the like. The most preferred vectors are plasmids.

When preparing an expression vector the skilled artisan understands that there are many variables to be considered, for example, whether to use a constitutive or inducible promoter. The practitioner also understands that the amount of nucleic acid or protein to be produced dictates, in part, the selection of the expression system. Regarding promoter sequences, inducible promoters are

-38-

preferred because they enable high level, regulatable expression of an operably-linked gene. The skilled artisan will recognize a number of suitable promoters that respond to a variety of inducers, for example, carbon source, metal ions, and heat. Other relevant considerations regarding an expression vector include whether to include sequences for directing the localization of a recombinant protein. For example, a sequence encoding a signal peptide preceding the coding region of a gene is useful for directing the extra-cellular export of a resulting polypeptide.

The present invention also provides a method for constructing a recombinant host cell capable of expressing LP8 proteins and analogs (e.g. SEQ ID NO:2), said method comprising transforming or otherwise introducing into a host cell a recombinant DNA vector that comprises an isolated DNA sequence that encodes SEQ ID NO:2 or analog thereof. A suitable host cell is any eucaryotic cell that can accomodate high level expression of an exogenously introduced gene or protein, and that will incorporate said protein into its membrane structure. Vectors for expression are those which comprise SEQ ID NO:1 or fragment thereof. Transformed host cells may be cultured under conditions well known to skilled artisans such that SEQ ID NO:2 is expressed, thereby producing a recombinant LP8 protein in the recombinant host cell.

For the purpose of identifying compounds having utility as inhibitors of tumor growth, for example, in a treatment of cancer, it would be desirable to identify compounds that bind the LP8 protein and/or modify or

-39-

antagonize its activity. A method for determining agents that bind the LP8 protein comprises contacting the LP8 protein with a test compound and monitoring binding by any suitable means.

5 The instant invention provides a screening system for discovering compounds that bind the LP8 protein, said screening system comprising the steps of:

- a) preparing LP8 protein;
- b) exposing said LP8 protein to a test compound;
- 10 c) quantifying the binding of said compound to LP8 protein by any suitable means.

Utilization of the screening system described above provides a means to determine compounds that may alter
15 the biological function of LP8. This screening method may be adapted to large-scale, automated procedures such as a PANDEX[®] (Baxter-Dade Diagnostics) system, allowing for efficient high-volume screening of potential therapeutic agents.

20 In such a screening protocol LP8 is prepared as described herein, preferably using recombinant DNA technology. A test compound is introduced into a reaction vessel containing the LP8 protein or fragment thereof. Binding of LP8 by a test compound is determined by any
25 suitable means. For example, in one method radioactively-labeled or chemically-labeled test compound may be used. Binding of the protein by the compound is assessed, for

-40-

example, by quantifying bound label versus unbound label using any suitable method. Binding of a test compound may also be carried out by a method disclosed in U.S. Patent 5,585,277, which hereby is incorporated by reference. In
5 this method, binding of a test compound to a protein is assessed by monitoring the ratio of folded protein to unfolded protein, for example by monitoring sensitivity of said protein to a protease, or amenability to binding of
said protein by a specific antibody against the folded state
10 of the protein.

The foregoing screening methods are useful for identifying a ligand, for example, an antagonist of a LP8 protein, as a lead to a pharmaceutical compound for the treatment of cancer, or for inhibiting tumor growth or for
15 inhibiting tissue growth, for example smooth muscle tissue growth. A ligand that binds LP8, or related fragment thereof, is identified, for example, by combining a test ligand with LP8 under conditions that cause the protein to exist in a ratio of folded to unfolded states. If the test
20 ligand binds the folded state of the protein, the relative amount of folded protein will be higher than in the case of a test ligand that does not bind the protein. The ratio of protein in the folded versus unfolded state is easily determinable by, for example, susceptibility to digestion by
25 a protease, or binding to a specific antibody, or binding to chaperonin protein, or binding to any suitable surface.

LP8 Protein Therapeutic Applications

In one embodiment, the present invention relates to therapeutic applications in which mitogenesis or the

-41-

inhibition thereof is therapeutically beneficial. For example, LP8 may be administered to enhance wound healing where such would be beneficial. For example, LP8 can be administered post-operatively to facilitate recovery from surgery. In another example, LP8 can be administered to treat chronic wounds, for example in the treatment of diabetic foot ulcerations.

In another embodiment an LP8 antagonist is administered as a means to prevent, or treat, or inhibit the development or progress of atherosclerosis, or atherosclerotic plaques. Since LP8 stimulates smooth muscle growth, antagonists thereof are expected to provide a means to prevent or treat atherosclerosis. For example, an LP8 antagonist can be administered simultaneously with, and/or as an adjunct treatment or procedure following angioplastic clearing or removal of atherosclerotic plaques from blood vessels. Alternatively, LP8 antagonists can be administered as a therapeutic treatment to prevent or restrict the progress of atherosclerosis apart from angioplastic treatment.

The present invention also provides methods for treating cancer and for inhibiting tumor growth, in vitro or in vivo, comprising administration of an effective amount of an LP8 antagonist.

For therapeutic utility in which enhanced mitogenesis is advantageous, an effective amount of LP8 protein is administered to an organism in need thereof in a dose between about 0.1 and 1000 ug/kg body weight. In practicing the methods contemplated by this invention, LP8

-42-

can be administered in a single daily dose or in multiple doses per day. The amount per administration will be determined by the physician and depend on such factors as the nature and severity of the disease, and the age and
5 general health of the patient.

The present invention also provides a pharmaceutical composition comprising as the active agent a LP8 polypeptide or fragment thereof, or a pharmaceutically acceptable non-toxic salt thereof, and a pharmaceutically
10 acceptable solid or liquid carrier. For example, compounds comprising LP8 can be admixed with conventional pharmaceutical carriers and excipients, and used in the form of tablets, capsules, elixirs, suspensions, syrups, wafers, and the like. The compositions comprising LP8 will contain
15 from about 0.1% to 90% by weight of the active compound, and more generally from about 10% to 30%. The compositions may contain common carriers and excipients such as corn starch or gelatin, lactose, sucrose, microcrystalline cellulose, kaolin, mannitol, dicalcium phosphate, sodium chloride, and
20 alginic acid. The compounds can be formulated for oral or parenteral administration.

For intravenous (IV) use, the LP8 protein is administered in commonly used intravenous fluid(s) and administered by infusion. Such fluids, for example,
25 physiological saline, Ringer's solution or 5% dextrose solution can be used.

For intramuscular preparations, a sterile formulation, preferably a suitable soluble salt form of the LP8 protein, for example SEQ ID NO:2, such as the

-43- /

hydrochloride salt, can be dissolved and administered in a pharmaceutical diluent such as pyrogen-free water (distilled), physiological saline or 5% glucose solution. A suitable insoluble form of the compound may be prepared and administered as a suspension in an aqueous base or a pharmaceutically acceptable oil base, e.g. an ester of a long chain fatty acid such as ethyl oleate.

The present invention also provides a pharmaceutical composition comprising as the active agent an antagonist of LP8, or a pharmaceutically acceptable non-toxic salt thereof, and a pharmaceutically acceptable solid or liquid carrier. For example, compounds comprising LP8 antagonist can be admixed with conventional pharmaceutical carriers and excipients, and used in the form of tablets, capsules, elixirs, suspensions, syrups, wafers, and the like. The compositions comprising LP8 will contain from about 0.1% to 90% by weight of the active compound, and more generally from about 10% to 30%. The compositions may contain common carriers and excipients such as corn starch or gelatin, lactose, sucrose, microcrystalline cellulose, kaolin, mannitol, dicalcium phosphate, sodium chloride, and alginic acid. The compounds can be formulated for oral or parenteral administration.

Skilled artisans will recognize that IC₅₀ values are dependent on the selectivity of the compound tested. For example, a compound with an IC₅₀ which is less than 10 nM is generally considered an excellent candidate for drug therapy. However, a compound which has a lower affinity, but is selective for a particular target, may be an even

-44-

better candidate. The skilled artisan will recognize that any information regarding the binding potential, inhibitory activity, or selectivity of a particular compound is useful toward the development of pharmaceutical products.

5 The following examples more fully describe the present invention. Those skilled in the art will recognize that the particular reagents, equipment, and procedures described are merely illustrative and are not intended to limit the present invention in any manner.

EXAMPLE 1

RT-PCR Amplification of LP8 Gene from mRNA

10 A LP8 gene is isolated by reverse transcriptase PCR (RT-PCR) using conventional methods. Total RNA from a
15 tissue that expresses the LP8 gene, for example placenta, is prepared using standard methods. First strand cDNA synthesis is achieved using a commercially available kit
(SuperScript™ System; Life Technologies) in conjunction with specific primers directed at any suitable region of SEQ
20 ID NO:1, for example between residues 276 and 1310.

 Amplification is carried out by adding to the first strand cDNA (dried under vacuum): 8 µl of 10X synthesis buffer (200 mM Tris-HCl, pH 8.4; 500 mM KCl, 25 mM MgCl₂, 1 ug/ul BSA); 68 µl distilled water; 1 µl each of a
25 10 uM solution of each primer; and 1 µl Taq DNA polymerase (2 to 5 U/µl). The reaction is heated at 94° C for 5 min. to denature the RNA/cDNA hybrid. Then, 15 to 30 cycles of PCR amplification are performed using any suitable thermal cycle apparatus. The amplified sample may be analyzed by agarose

-45-

gel electrophoresis to check for an appropriately-sized fragment.

EXAMPLE 2

5 Production of a Vector for Expressing LP8 in a Host Cell

 An expression vector suitable for expressing LP8 or fragment thereof in a variety of procaryotic host cells, such as *E. coli* is easily made. The vector contains an origin of replication (Ori), an ampicillin resistance gene
10 (Amp) useful for selecting cells which have incorporated the vector following a transformation procedure, and further comprises the T7 promoter and T7 terminator sequences in operable linkage to a LP8 coding region. Plasmid pET28A (obtained from Novogen, Madison WI) is a suitable parent
15 plasmid. PET28A is linearized by restriction with endonucleases NdeI and BamHI and ligated to a DNA fragment bearing NdeI and BamHI sticky ends comprising the coding region of the LP8 gene as disclosed by SEQ ID NO:1 viz. Residues 276 through 1310, or fragment thereof.

20 The LP8 gene used in this construction may be slightly modified at the 5' end (amino terminus of encoded protein) in order to simplify purification of the encoded protein product. For this purpose, an oligonucleotide encoding 8 histidine residues is inserted after the ATG
25 start codon. Placement of the histidine residues at the amino terminus of the encoded protein serves to enable the IMAC one-step protein purification procedure.

-46-

EXAMPLE 3

Recombinant Expression of a Secreted LP8 Protein

An expression vector that carries an ORF encoding residues 16 through 345 of SEQ ID NO:2 and further comprising a kappa chain signal peptide fused at the amino terminus of said residue 16 was operably-linked to an CMV promoter in plasmid pcDNA3 and transfected into 293 T cells using standard methods. Transfectants were analyzed for transient expression of LP8 using Western blot analysis. The results showed that the truncated LP8 protein was secreted into the culture medium.

EXAMPLE 4

Detecting Ligands that Bind LP8 Using a Chaperonin Protein Assay

The wells of an ELISA plate are coated with chaperonin by incubation for several hours with a 4 ug/ml solution of the protein in Tris-buffered Saline (TBS: 10 mM Tris-HCl, pH7.5, 0.2M NaCl). The plates are then washed 3 times with TBS containing 0.1% Tween-20 (TBST). Then, a mixture of LP8 protein (sufficient amount to saturate about 50% of the binding sites on chaperonin) and test compound (10^{-9} to 10^{-5} M) in about 50 μ l volume is added to each well of the plate for an incubation of about 60 minutes. Aliquots of the well solutions are then transferred to the wells of fresh plates and incubated for 60 minutes at room temperature, followed by 3 washes with TBST. Next, about 50 μ l of an antibody specific for LP8 plus 5% nonfat dry milk are added to each

-47-

well for a 30 minute incubation at room temperature. After washing, about 50 μ l of goat anti-rabbit IgG alkaline phosphatase conjugate at an appropriate dilution in TBST plus 5% nonfat dry milk are added to each well and incubated 5 30 minutes at room temperature. The plates are washed again with TBST and 0.1 ml of 1 mg/ml p-nitrophenylphosphate in 0.1% diethanolamine is added. Color development (proportional to bound alkaline phosphatase antibody conjugate) is monitored with an ELISA plate reader. When 10 test ligand binding has occurred, ELISA analysis reveals LP8 in solution at higher concentrations than in the absence of test ligand.

EXAMPLE 5

15 Production of an Antibody to LP8 Protein

Substantially pure LP8 protein or fragment thereof is isolated from transfected or transformed cells using any of the well known methods in the art, or by a method specifically disclosed herein. Concentration of protein in a 20 final preparation is adjusted, for example, by filtration through an Amicon filter device such that the level is about 1 to 5 μ g/ml. Monoclonal or polyclonal antibody can be prepared as follows.

Monoclonal antibody can be prepared from murine 25 hybridomas according to the method of Kohler and Milstein (Nature, 256, 495, 1975), or a modified method thereof. Briefly, a mouse is repetitively inoculated with a few micrograms of the protein or fragment thereof, or fusion peptide thereof, over a period of a few weeks. The mouse is

-48-

then sacrificed and the antibody producing cells of the spleen isolated. The spleen cells are fused by means of polyethylene glycol with mouse myeloma cells. Fused cells that produce antibody are identified by any suitable immunoassay, for example, ELISA, as described in E. Engvall, 5 *Meth. Enzymol.*, 70, 419, 1980.

Polyclonal antiserum can be prepared by well known methods (See e.g. J. Vaitukaitis et.al. *Clin. Endocrinol. Metab.* 33, 988, 1971) that involve immunizing suitable 10 animals with the proteins, fragments thereof, or fusion proteins thereof, disclosed herein. Small doses (e.g. nanogram amounts) of antigen administered at multiple intradermal sites appears to be the most reliable method.

15

EXAMPLE 6

Endothelial Cell Growth Assay

For conducting the cell growth assay, approximately 3000 human umbilical vein endothelial cells were grown in 96 well TC plates in 150 ul Media 199/10% fetal calf serum with 20 and without LP8. In some experiments, *E. coli* produced LP8 was used, in other experiments a mammalian produced LP8 containing a FLAG peptide was used. The LP8 was added to a final concentration of 6 ng/ml.

After 24 hours post-plating, approximately 0.25 uCi ³H- 25 thymidine was added to each well. Forty-eight hours later, plates were frozen at - 70 C, thawed, cells harvested onto filter paper and the samples counted in a scintillation counter.

-49-

EXAMPLE 7

Assay for LP8 Antagonist

Assay reactions are set up essentially as described in Example 6, except that a compound to be tested for LP8 antagonist activity is included at the step of adding conditioned medium to bovine capillary endothelial cells. Multiple assays can be set up in which a constant amount of conditioned medium is incubated with varying amounts of test compound, for example from about 10 ng/ml to about 100 ug/ml.

For conducting the cell growth assay, bovine capillary endothelial cells are maintained in DMEM containing 20% calf serum according to the method of Ferrara, Biochem. Biophys. Res. Comm., 161, 851-58, 1989. Cells are plated at about 8×10^3 cells per well in 12 well plates in DMEM supplemented with 10% calf serum, 2 mM glutamine, and antibiotics. Conditioned medium from transiently transfected 293 cells 72 hours post-transfection is added and cell number determined after 5 days.

EXAMPLE 8

LP8 Exposure to Cell Proliferation Panel

The following cell panels were exposed to LP8 and assayed for resulting cell proliferation.

CTL.L.6 (murine)

Cytotoxic T-cell line, from C57/B1/6 mice, lymphoblast morphology, IL-2 dependent

MTS proliferation assays

-50-

Growth Medium: RPMI 1640/L-Glu + 10%FBS + 1mM Sodium
Pyruvate + 10mM HEPES + 5×10^{-5} M 2-Me + 2ng/ml IL-2
Assay Medium: RPMI 1640/L-Glu + 10%FBS + 1mM Sodium
Pyruvate + 10mM HEPES + 5×10^{-5} M 2-Me

5

T1165.17 (murine)

Plasmacytoma cell line (originates from B-cell), from
ascites tumors of Balb/CAnPt mice

IL-1? dependent

10 MTS proliferation assay

Growth Medium: RPMI 1640/L-Glu + 10%FBS + 1mM Sodium
Pyruvate + 10mM HEPES + 5×10^{-5} M 2-Me + 2ng/ml rhIL-1?
Assay Medium: RPMI 1640/L-Glu + 10%FBS + 1mM Sodium
Pyruvate + 10mM HEPES + 5×10^{-5} M 2-Me

15

BalbC/3T3 Clone A31 (murine)

From 14 - 17-day-old Balb/C mouse embryos, fibroblast
morphology, non-tumorigenic, contact-inhibited

^3H Thymidine uptake proliferation assays

20 Growth Medium: DMEM + 10% Calf Serum

Assay medium: DMEM + 2% Plasma Dialyzed Calf Serum

TF.1 (human)

Erythroleukemia, lymphoblast morphology

25 hGM-CSF dependent

MTS proliferation assays

Growth Medium: RPMI 1640/L-Glu + 10%FBS + 1mM Sodium
Pyruvate + 10mM HEPES + 5×10^{-5} M 2-Me + 5ng/ml rhGM-CSF

-51-

Assay Medium: RPMI 1640/L-Glu + 10%FBS + 1mM Sodium
Pyruvate + 10mM HEPES + 5×10^{-5} M 2-Me

MCF-7 (human)

- 5 Breast cancer cell line, epithelial morphology

^3H Thymidine uptake proliferation assays

Responds by growth to insulin

Growth Medium: Eagles MEM (w/o phenol red) + 10%FBS + 1mM
Sodium Pyruvate + Nonessential Amino Acids + L-Glu + 1ug/ml
10 insulin

Assay Medium: Eagles MEM (w/o phenol red) + 1mM Sodium
Pyruvate + Nonessential Amino Acids + L-Glu + 10ug/ml human
transferrin

- 15 HUVEC (human)

Umbilical vein endothelial cells, primary

^3H Thymidine uptake proliferation assays

Growth Medium: Clonetics complete endothelial growth medium

Assay Medium: Medium 199 + 10%FBS

-52-

Comments

While LP8 produced in mammalian cells showed mitogenic activity on BalbC/3T3 cells, *E.coli* expressed LP8 did not (see Figure 2). All positive controls (i.e. human FGF-2) showed the activity expected.

EXAMPLE 9LP8 Stimulates Human Aortic Smooth Muscle Cells

10 Approximately 5000 human aortic smooth muscle cells were seeded per well in a 96 well plate containing smooth muscle growth media (SMGM) from Clonetics. Cells were grown overnight in an incubator. After overnight incubation, SMGM was replaced with 100 ul/well smooth muscle basal media
15 (SMBM). Cells were starved in SMGM for 48 hours in the incubator. Next, growth factors diluted in SMBM were added to each well. Human PDGF, isolated from human platelets, was purchased from R & D Systems (cat # 120-HD-001). The final volume per well was 200 ul. Cells were incubated for
20 approximately 20 hours.

To assess the effect on cell proliferation approximately 0.25uCi ³H-thymidine was added to each well for 4 hours in the incubator. Cells were harvested and the quantity of radioactivity taken up by the cells was
25 determined using a scintillation counter (See Figure 4).

EXAMPLE 10LP8 Stimulates BalbC/3T3 Cell Proliferation

In these experiments approximately 5000 BalbC/3T3 cells
30 were seeded per well in a 96 well plate in DMEM/10% calf

-53-

serum. The cells were grown for two days in an incubator to achieve approximately 90-100% confluence. Then, cells were starved in DMEM/2% dialyzed calf serum for 24 hours in the incubator and growth factors were added diluted in DMEM/2% dialyzed calf serum. The final volume per well was 200 ul. Cells were incubated an additional 16-18 hours.

To assess the effects of LP8 and other growth factors on cell proliferation, each well received 0.25uCi ³H-thymidine during a 2 hour pulse in the incubator. Cells were then harvested and counted in a scintillation counter.

Human PDGF, isolated from human platelets, was purchased from R & D Systems (cat # 120-HD-001). Figure 3 shows that LP8 stimulated thymidine uptake when added at 1 - 5 ng/ml protein.

-54-

WE CLAIM:

1. A method for enhancing tissue growth by
administration of a therapeutically effective amount of LP8
5 protein or analog thereof.

2. A method for promoting wound healing by
administration of a therapeutically effective amount of an
LP8 protein or analog thereof to a patient in need thereof.
10

3. A method for stimulating smooth muscle growth
comprising the step of administering an effective amount of
LP8 or analog thereof.

15 4. A method, as in any one of claims 1 to 3, wherein
said LP8 is SEQ ID NO:2.

5. A method, as in any one of claims 1 to 3, wherein
said LP8 is at least 80% identical with SEQ ID NO:2.
20

6. A method, as in any one of claims 1 to 3, wherein
said LP8 analog is encoded by a nucleic acid that hybridizes
to residues 276 through 1310 of SEQ ID NO:1 under high
stringency conditions.
25

7. A method for slowing the progress of atherosclerosis
by administration of a therapeutically effective amount of
LP8 antagonist.

-55-

8. A method for treating atherosclerosis by administration of a therapeutically effective amount of LP8 antagonist.

5

FIG. 1




FIG. 2




FIG. 3





FIG. 4



SEQUENCE LISTING

<110> Eli Lilly and Company

<120> Platelet-derived growth factor related gene and protein

<130> X-12886

<140>

<141>

<160> 2

<170> PatentIn Ver. 2.0

<210> 1

<211> 2898

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (276)..(1310)

<400> 1

```

cttcgccaca gctcaggatt tgtttaaac ttgggtaaac tgggttcaggt ccaggttttg 60
ctttgatcct tttcaaaaac tggatacaca gaagagggt ctaggaaaaa gttttggatg 120
ggattatgtg gaaactaccc tgcgattctc tgcgtccaga gcaggctcgg cgcttccacc 180
ccagtgcagc cttccctcgg cggtggtgaa agagactcgg gagtcgctgc ttccaaagtg 240
cccgccgtga gtgagctctc accccagtca gccaa atg agc ctc ttc ggg ctt 293
                               Met Ser Leu Phe Gly Leu
                               1           5

ctc ctg ctg aca tct gcc ctg gcc ggc cag aga cag ggg act cag gcg 341
Leu Leu Leu Thr Ser Ala Leu Ala Gly Gln Arg Gln Gly Thr Gln Ala
          10           15           20

gaa tcc aac ctg agt agt aaa ttc cag ttt tcc agc aac aag gaa cag 389
Glu Ser Asn Leu Ser Ser Lys Phe Gln Phe Ser Ser Asn Lys Glu Gln
          25           30           35

aac gga gta caa gat cct cag cat gag aga att att act gtg tct act 437
Asn Gly Val Gln Asp Pro Gln His Glu Arg Ile Ile Thr Val Ser Thr
          40           45           50

aat gga agt att cac agc cca agg ttt cct cat act tat cca aga aat 485
Asn Gly Ser Ile His Ser Pro Arg Phe Pro His Thr Tyr Pro Arg Asn
          55           60           65           70

acg gtc ttg gta tgg aga tta gta gca gta gag gaa aat gta tgg ata 533
Thr Val Leu Val Trp Arg Leu Val Ala Val Glu Glu Asn Val Trp Ile

```

| 75 | | | | | | | | | | 80 | | | | | 85 | | | | | |
|---|------|--|--|--|--|--|--|--|--|----|--|--|--|--|----|--|--|--|--|--|
| caa ctt acg ttt gat gaa aga ttt ggg ctt gaa gac cca gaa gat gac | 581 | | | | | | | | | | | | | | | | | | | |
| Gln Leu Thr Phe Asp Glu Arg Phe Gly Leu Glu Asp Pro Glu Asp Asp | | | | | | | | | | | | | | | | | | | | |
| 90 95 100 | | | | | | | | | | | | | | | | | | | | |
| ata tgc aag tat gat ttt gta gaa gtt gag gaa ccc agt gat gga act | 629 | | | | | | | | | | | | | | | | | | | |
| Ile Cys Lys Tyr Asp Phe Val Glu Val Glu Glu Pro Ser Asp Gly Thr | | | | | | | | | | | | | | | | | | | | |
| 105 110 115 | | | | | | | | | | | | | | | | | | | | |
| ata tta ggg cgc tgg tgt ggt tct ggt act gta cca gga aaa cag att | 677 | | | | | | | | | | | | | | | | | | | |
| Ile Leu Gly Arg Trp Cys Gly Ser Gly Thr Val Pro Gly Lys Gln Ile | | | | | | | | | | | | | | | | | | | | |
| 120 125 130 | | | | | | | | | | | | | | | | | | | | |
| tct aaa gga aat caa att agg ata aga ttt gta tct gat gaa tat ttt | 725 | | | | | | | | | | | | | | | | | | | |
| Ser Lys Gly Asn Gln Ile Arg Ile Arg Phe Val Ser Asp Glu Tyr Phe | | | | | | | | | | | | | | | | | | | | |
| 135 140 145 150 | | | | | | | | | | | | | | | | | | | | |
| cct tct gaa cca ggg ttc tgc atc cac tac aac att gtc atg cca caa | 773 | | | | | | | | | | | | | | | | | | | |
| Pro Ser Glu Pro Gly Phe Cys Ile His Tyr Asn Ile Val Met Pro Gln | | | | | | | | | | | | | | | | | | | | |
| 155 160 165 | | | | | | | | | | | | | | | | | | | | |
| ttc aca gaa gct gtg agt cct tca gtg cta ccc cct tca gct ttg cca | 821 | | | | | | | | | | | | | | | | | | | |
| Phe Thr Glu Ala Val Ser Pro Ser Val Leu Pro Pro Ser Ala Leu Pro | | | | | | | | | | | | | | | | | | | | |
| 170 175 180 | | | | | | | | | | | | | | | | | | | | |
| ctg gac ctg ctt aat aat gct ata act gcc ttt agt acc ttg gaa gac | 869 | | | | | | | | | | | | | | | | | | | |
| Leu Asp Leu Leu Asn Asn Ala Ile Thr Ala Phe Ser Thr Leu Glu Asp | | | | | | | | | | | | | | | | | | | | |
| 185 190 195 | | | | | | | | | | | | | | | | | | | | |
| ctt att cga tat ctt gaa cca gag aga tgg cag ttg gac tta gaa gat | 917 | | | | | | | | | | | | | | | | | | | |
| Leu Ile Arg Tyr Leu Glu Pro Glu Arg Trp Gln Leu Asp Leu Glu Asp | | | | | | | | | | | | | | | | | | | | |
| 200 205 210 | | | | | | | | | | | | | | | | | | | | |
| cta tat agg cca act tgg caa ctt ctt ggc aag gct ttt gtt ttt gga | 965 | | | | | | | | | | | | | | | | | | | |
| Leu Tyr Arg Pro Thr Trp Gln Leu Leu Gly Lys Ala Phe Val Phe Gly | | | | | | | | | | | | | | | | | | | | |
| 215 220 225 230 | | | | | | | | | | | | | | | | | | | | |
| aga aaa tcc aga gtg gtg gat ctg aac ctt cta aca gag gag gta aga | 1013 | | | | | | | | | | | | | | | | | | | |
| Arg Lys Ser Arg Val Val Asp Leu Asn Leu Leu Thr Glu Glu Val Arg | | | | | | | | | | | | | | | | | | | | |
| 235 240 245 | | | | | | | | | | | | | | | | | | | | |
| tta tac agc tgc aca cct cgt aac ttc tca gtg tcc ata agg gaa gaa | 1061 | | | | | | | | | | | | | | | | | | | |
| Leu Tyr Ser Cys Thr Pro Arg Asn Phe Ser Val Ser Ile Arg Glu Glu | | | | | | | | | | | | | | | | | | | | |
| 250 255 260 | | | | | | | | | | | | | | | | | | | | |
| cta aag aga acc gat acc att ttc tgg cca ggt tgt ctc ctg gtt aaa | 1109 | | | | | | | | | | | | | | | | | | | |
| Leu Lys Arg Thr Asp Thr Ile Phe Trp Pro Gly Cys Leu Leu Val Lys | | | | | | | | | | | | | | | | | | | | |
| 265 270 275 | | | | | | | | | | | | | | | | | | | | |
| cgc tgt ggt ggg aac tgt gcc tgt tgt ctc cac aat tgc aat gaa tgt | 1157 | | | | | | | | | | | | | | | | | | | |
| Arg Cys Gly Gly Asn Cys Ala Cys Cys Leu His Asn Cys Asn Glu Cys | | | | | | | | | | | | | | | | | | | | |
| 280 285 290 | | | | | | | | | | | | | | | | | | | | |

caa tgt gtc cca agt aaa gtt act aaa aaa tac cac gag gtc ctt cag 1205
 Gln Cys Val Pro Ser Lys Val Thr Lys Lys Tyr His Glu Val Leu Gln
 295 300 305 310

ttg aga cca aag acc ggt gtc agg gga ttg cac aaa tca ctc acc gac 1253
 Leu Arg Pro Lys Thr Gly Val Arg Gly Leu His Lys Ser Leu Thr Asp
 315 320 325

gtg gcc ctg gag cac cat gag gag tgt gac tgt gtg tgc aga ggg agc 1301
 Val Ala Leu Glu His His Glu Glu Cys Asp Cys Val Cys Arg Gly Ser
 330 335 340

aca gga gga tagccgcac accaccagca gctcttgccc agagctgtgc 1350
 Thr Gly Gly
 345

agtgcagtgg ctgattctat tagagaacgt atgcggttacc tccatcctta atctcagttg 1410

tttgcttcaa ggacctttca tcttcaggat ttacagtgc ctcgtgaaaga ggagacatca 1470

aacagaatta ggagttgtgc aacagctctt ttgagaggag gcctaaagga caggagaaaa 1530

ggtcttcaat cgtggaaaga aaattaaatg ttgtattaaa tagatcacca gctagtttca 1590

gagttaccat gtacgtattc cactagctgg gttctgtatt tcagttcttt cgatacggct 1650

tagggtaatg tcagtacagg aaaaaactgt gcaagtgagc acctgattcc gttgccttgc 1710

ttaactctaa agctccatgt cctgggccta aaatcgtata aaatctggat tttttttttt 1770

ttttttgctc atattcacat atgtaaacca gaacattcta tgtactacaa acctgggtttt 1830

taaaaaggaa ctatgttgct atgaattaaa cttgtgtcat gctgatagga caggctggat 1890

ttttcatatt tcttattaaa atttctgcc tttagaagaa gagaactaca ttcattggttt 1950

ggaagagata aacctgaaaa gaagagtggc cttatcttca ctttatcgat aagtcagttt 2010

atttgtttca ttgtgtacat ttttatattc tccttttgac attataactg ttggcttttc 2070

taatcttggt aaatatatct atttttacca aaggatttta atattctttt ttatgacaac 2130

ttagatcaac tatttttagc ttggtaaatt tttctaaaca caattgttat agccagagga 2190

acaaagatga tataaaatat tgttgctctg acaaaaatac atgtatttca ttctcgtatg 2250

gtgctagagt tagattaatc tgcattttta aaaactgaat tggaatagaa ttggtaagtt 2310

gcaaagactt tttgaaaata attaaattat catatcttcc attcctgtta ttggagatga 2370

aaataaaaag caacttatga aagtagacat tcagatccag ccattactaa cctattcctt 2430

tttttgggga aatctgagcc tagctcagaa aaacataaag caccttgaaa aagacttggc 2490

agcttcctga taaagcgtgc tgtgctgtgc agtaggaaca catcctatattt attgtgatgt 2550
 tgtgggtttta ttatctttaa ctctgttcca tacacttgta taaatacatg gatattttta 2610
 tgtacagaag tatgtctctt aaccagttca cttattgtac tcaggcaatt taaaagaaaa 2670
 tcagtaaaat attttgcttg taaaatgctt aatatcgtgc ctaggttatg tggtgactat 2730
 ttgaatcaaa aatgtattga atcatcaaat aaaagaatgt ggctattttg gggagaaaag 2790
 taaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaagcg gcgctgaat tacctgcccg 2850
 ggcgggcgct ccaaccctat agtgagtag ccgaattcca gcacactg 2898

<210> 2
 <211> 345
 <212> PRT
 <213> Homo sapiens

<400> 2
 Met Ser Leu Phe Gly Leu Leu Leu Leu Thr Ser Ala Leu Ala Gly Gln
 1 5 10 15
 Arg Gln Gly Thr Gln Ala Glu Ser Asn Leu Ser Ser Lys Phe Gln Phe
 20 25 30
 Ser Ser Asn Lys Glu Gln Asn Gly Val Gln Asp Pro Gln His Glu Arg
 35 40 45
 Ile Ile Thr Val Ser Thr Asn Gly Ser Ile His Ser Pro Arg Phe Pro
 50 55 60
 His Thr Tyr Pro Arg Asn Thr Val Leu Val Trp Arg Leu Val Ala Val
 65 70 75 80
 Glu Glu Asn Val Trp Ile Gln Leu Thr Phe Asp Glu Arg Phe Gly Leu
 85 90 95
 Glu Asp Pro Glu Asp Asp Ile Cys Lys Tyr Asp Phe Val Glu Val Glu
 100 105 110
 Glu Pro Ser Asp Gly Thr Ile Leu Gly Arg Trp Cys Gly Ser Gly Thr
 115 120 125
 Val Pro Gly Lys Gln Ile Ser Lys Gly Asn Gln Ile Arg Ile Arg Phe
 130 135 140
 Val Ser Asp Glu Tyr Phe Pro Ser Glu Pro Gly Phe Cys Ile His Tyr
 145 150 155 160
 Asn Ile Val Met Pro Gln Phe Thr Glu Ala Val Ser Pro Ser Val Leu
 165 170 175

Pro Pro Ser Ala Leu Pro Leu Asp Leu Leu Asn Asn Ala Ile Thr Ala
 180 185 190

Phe Ser Thr Leu Glu Asp Leu Ile Arg Tyr Leu Glu Pro Glu Arg Trp
 195 200 205

Gln Leu Asp Leu Glu Asp Leu Tyr Arg Pro Thr Trp Gln Leu Leu Gly
 210 215 220

Lys Ala Phe Val Phe Gly Arg Lys Ser Arg Val Val Asp Leu Asn Leu
 225 230 235 240

Leu Thr Glu Glu Val Arg Leu Tyr Ser Cys Thr Pro Arg Asn Phe Ser
 245 250 255

Val Ser Ile Arg Glu Glu Leu Lys Arg Thr Asp Thr Ile Phe Trp Pro
 260 265 270

Gly Cys Leu Leu Val Lys Arg Cys Gly Gly Asn Cys Ala Cys Cys Leu
 275 280 285

His Asn Cys Asn Glu Cys Gln Cys Val Pro Ser Lys Val Thr Lys Lys
 290 295 300

Tyr His Glu Val Leu Gln Leu Arg Pro Lys Thr Gly Val Arg Gly Leu
 305 310 315 320

His Lys Ser Leu Thr Asp Val Ala Leu Glu His His Glu Glu Cys Asp
 325 330 335

Cys Val Cys Arg Gly Ser Thr Gly Gly
 340 345